Compare · AZN vs EGRX
AZN vs EGRX
Side-by-side comparison of AstraZeneca PLC (AZN) and Eagle Pharmaceuticals Inc. (EGRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and EGRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN carries a market cap of $270.37B.
- AZN has been more active in the news (23 items in the past 4 weeks vs 1 for EGRX).
- AZN has more recent analyst coverage (25 ratings vs 2 for EGRX).
- Company
- AstraZeneca PLC
- Eagle Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $270.37B
- -
- 1M return
- +1.07%
- -
- 1Y return
- +91.63%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2014
- News (4w)
- 23
- 1
- Recent ratings
- 25
- 2
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Latest AZN
- Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Latest EGRX
- Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
- Glancy Prongay Wolke & Rotter LLP, as Lead Counsel, Obtained $9.5 Million Settlement for Eagle Pharmaceuticals, Inc. Investors
- Eagle Pharmaceuticals Announces Divestiture of Barhemsys
- Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
- Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders
- Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements
- Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
- Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
- Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors
- Eagle Pharmaceuticals Announces 2025 Annual Meeting Date